Jersey City, N.J.-based Character Biosciences has raised $93 million in a series B financing round. The funding will be used to advance the company’s pipeline of therapies to treat degenerative eye diseases, starting with age-related macular degeneration, according to a March 25 news release from the company. Character Biosciences has partnered with more than 150 […]
The post Character Biosciences earns $93M investment to treat degenerative eye diseases appeared first on Becker’s ASC.